nach oben

Rheumatology International

Erschienen in:

01.03.2012 | Original Article

Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice

verfasst von: Chunyan He, Xuehong Lu, Zhaowei Yan, Man Wu, Shujun Liu, Yongli Yu, Ping Luo

Erschienen in: Rheumatology International | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Mice with chronic graft-versus-host disease (cGVHD) induced by transferring parental BALB/C lymphocytes into (C57BL/6 × BALB/C) F1 (CBF1) hybrids, develop a syndrome characterized by B-cell hyperactivity, autoantibody production, and immune complex-mediated glomerulonephritis. In this model, we evaluated the role of leflunomide on the development of lupus nephritis in system autoimmunity. Daily administration of leflunomide (15 mg/kg/d) from 2 weeks after cGVHD induction can dramatically reduce the production of autoantibodies and immune complex deposition in the kidney, leading to relieved kidney damage and reduced mortality. The therapeutic effect of leflunomide on the lupus-prone mice was partially due to the inhibition of TLR9 signaling pathway, which was an important component of innate immune system.

Aurelia L, Philippe C, Isabelle A et al (2006) Role of TLR9 in anti-nucleosome and Anti-DNA antibody production in lpr mutation-induced murine lupus. J Immunol 177:1349–1354

Nagy G, Koncz A, Perl A (2005) T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol 25(2):123–140PubMedCrossRef

Hahn BH, Ebling F, Singh RR et al (2005) Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann N Y Acad Sci 1051:433–441PubMedCrossRef

Christensen SR, Kashgarian M, Alexopoulou L et al (2005) Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 202:321–331PubMedCrossRef

Nakano S, Morimoto S, Suzuki J et al (2008) Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology 47:145–149PubMedCrossRef

Laan RF, van Riel PL, van de Putte LB (2001) Leflunomide and methotrexate. Curr Opin Rheumatol 13(3):159–163PubMedCrossRef

Vidic-Dankovic B, Kosec D, Damjanovic M et al (1995) Leflunomide prevents the development of experimentally induced myasthenia gravis. Int J Immunopharmacol 17:273–281PubMedCrossRef

Bartlett RR, Anagnostopulos H, Zielinski T et al (1993) Effects of leflumomide on immune responses and models of inflammation. Springer Semin Immunopathol 14:381–394PubMedCrossRef

Thomas K, Klaus T, Hans-Peter H, Stefan J (2001) Suppression of experimental autoimmune neuritis by leflunomide. Brain 124:1791–1802CrossRef

10.

Wang HY, Cui TG, Hou FF et al (2008) Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 17(7):638–644PubMedCrossRef

11.

Zhang FS, Nie YK, Jin XM et al (2009) The efficacy and safety of lefunomide therapy in lupus nephritis by repeat kidney biopsy. Rheumatol Int 29(11):1331–1335PubMedCrossRef

12.

Tam LS, Li EK, Wong CK et al (2004) Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13(8):601–604PubMedCrossRef

13.

Wernick RM, Smith DL, Houghton DC et al (1993) Reliability of histologic scoring for lupus nephritis: a community-based evaluation. Ann Intern Med 119:805–811PubMed

14.

Trouw LA, Seelen MA, Duijs JM et al (2003) Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol 132:32–39PubMedCrossRef

15.

Van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ et al (1994) A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 174:311–320PubMedCrossRef

16.

Popovich S, Bartletr RR (1987) The use of the murine chronic graft versus host (CGVH) disease, a model for systemic lupus erythematosus (SLE) for drug discovery. Agents Actions 21:284CrossRef

17.

Bruijn JA, Van Elven EH, Hogendorn PCW et al (1988) Murine chronic graft versus host disease as a model for lupus nephritis. Am J Pathol 130:639PubMed

18.

Rolink AG, Radaszkiewicz T, Melchers F (1987) The autoantigen binding B cell repertoires of normal and of chronically graft versus host diseased mice. J Exp Med 165:1675PubMedCrossRef

19.

Vidic-Dankovic B, Kosec D, Damjanovic M et al (1995) Leflunomide prevents thedevelopment of experimentally induced myasthenia gravis. Int J Immunopharmacol 17(4):273–281PubMedCrossRef

20.

Means TK, Latz E, Hayashi F et al (2005) Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 115:407–417PubMed

21.

Rifkin IR, Leadbetter EA, Busconi L et al (2005) Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 205:27–42CrossRef

22.

Anders HJ, Banas B, Schlondorff D (2004) Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15:854–867PubMedCrossRef

23.

Imai H, Hamai K, Komatsuda A et al (1997) IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int 51:270–276PubMedCrossRef

24.

Grootscholten C, van Bruggen MC, van der Pijl JW et al (2003) Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum 48:1355–1362PubMedCrossRef

25.

Bootsma H, Spronk PE, Ter Borg EJ et al (1997) The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus: a prospective long-term observation. Ann Rheum Dis 56:661–666PubMedCrossRef

26.

Clough JD, Valenzuela R (1980) Relationship of renal histopathology in SLE nephritis to immunoglobulin class of anti-DNA. Am J Med 68:80–85PubMedCrossRef

27.

Taki S, Hirose S, Kinoshita K et al (1992) Somatically mutated IgG anti-DNA antibody clonally related to germ-line encoded IgM anti-DNA antibody. Eur J Immunol 22:987–992PubMedCrossRef

28.

Pisetsky DS, Jelinek DF, McAnally LM et al (1990) In vitro autoantibody production by normal adult and cord blood B cells. J Clin Invest 85:899–903PubMedCrossRef

29.

Witte T, Hartung K, Sachse C et al (1998) IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. Rheumatol Int 18:85–91PubMedCrossRef

30.

Forger F, Matthias T, Oppermann M et al (2004) Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 13:36–44PubMedCrossRef

Titel: Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice
verfasst von: Chunyan He
Xuehong Lu
Zhaowei Yan
Man Wu
Shujun Liu
Yongli Yu
Ping Luo
Publikationsdatum: 01.03.2012
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 3/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-010-1630-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

26.04.2024 | Hüft-TEP | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

The association of Raynaud’s syndrome with carpal tunnel syndrome: a meta-analysis

Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab

Enthesitis and its relationships with disease parameters in Moroccan patients with ankylosing spondylitis

Malignancies associated with systemic lupus erythematosus in Taiwan: a nationwide population-based cohort study

Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity

Painful myositis in the anti-synthetase syndrome with anti-PL12 antibodies

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Update Innere Medizin